Clinical Trials Logo

Filter by:
NCT ID: NCT06463821 Completed - Clinical trials for Symptom Spectrum and Risk Factors for Fever

Symptom Spectrum and Risk Factors for Fever in Pediatric and Adult Patients With Omicron Infection

Start date: April 8, 2022
Phase:
Study type: Observational

The omicron variant of coronavirus disease 2019 (COVID-19) has caused a global epidemic in 2022. The aim was to investigate the symptom spectrum and risk factors for fever in pediatric and adult patients with omicron infection. From April 8, 2022 to May 17, 2022, this prospective observational study included patients who attended the child-parent sections of the Fangcang shelter hospitals with laboratory-confirmed COVID-19. Patient data were collected from questionnaires. The risk factors for prolonged fever and high fever were identified by univariate and multivariate analyses.

NCT ID: NCT06463808 Recruiting - Clinical trials for Ventricular Remodeling

Effect of Recombinant Human Brain Natriuretic Peptide on Ventricular Remodeling and Cardiac Function in Patients With Acute Anterior Myocardial Infraction Undergoing Percutaneous Coronary Intervention

Start date: May 3, 2023
Phase:
Study type: Observational

This study is designed to evaluate the efficacy and safety of Recombinant Human Brain Natriuretic Peptide (rhBNP) in improving ventricular remodeling and cardiac function after acute anterior myocardial infarction undergoing percutaneous coronary intervention. 100 patients with acute anterior myocardial infarction after primary Percutaneous Coronary Intervention (pPCI) are randomly assigned 1:1 to rhBNP group(n=50) and control group(n=50) with follow-up of 24 weeks. Both groups are treated with standard therapy of AAMI, with the rhBNP group intravenous dripping rhBNP after pPCI for 3 days and the control group treated with placebo at the same time. The primary endpoint is the change in N terminal pro-B-type natriuretic peptide(NT-proBNP )and cardiac troponin T(cTnT) level.The secondary endpoint is the change in 24-week echocardiographic including left ventricle ejection fraction (LVEF) , left ventricular end-diastolic volume index (LVEDVI) and left ventricular end-systolic volume index (LVESVI), arrhythmia and cardiovascular events (death, cardiac arrest or cardiopulmonary resuscitation, hospitalization due to heart failure or angina pectoris).

NCT ID: NCT06463756 Recruiting - Laryngeal Carcinoma Clinical Trials

CT-based Radiomics and Deep Learning Models to Predict Thyroid Cartilage Invasion and Patient Prognosis in Laryngeal Carcinoma

Start date: August 13, 2023
Phase:
Study type: Observational

This retrospective study was to develop and verify a CT-based radiomics model, 2D deep learning model and 3D deep learning model to preoperatively predict the thyroid cartilage invasion of laryngeal cancer patients, so as to provide more accurate diagnosis and treatment basis for clinicians. And the performance of the aforementioned models was compared with two radiologists. In addition, the researchers investigated the prediction of survival outcomes of patients by the above optimal models.

NCT ID: NCT06463717 Recruiting - Multiple Myeloma Clinical Trials

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

Start date: December 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to compare the efficacy and safety of autologous hematopoietic stem-cell transplantation (ASCT) versus non ASCT regimens in primary multiple myeloma patients achieved MRD negativity after induction. The main question it aims to answer is: In primary multiple myeloma patients who achieved MRD negativity after induction, non ASCT regimens are not inferior to ASCT or not? Participants will receive ASCT or non ASCT regimen according to their own choice. Researchers will compare ASCT and non ASCT group see if any significant difference in efficacy and safety.

NCT ID: NCT06463548 Not yet recruiting - Clinical trials for Biliary Tract Carcinoma

Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

To evaluate the efficacy and safety of irinotecan hydrochloride liposome injection combined with Capecitabine and Lenvatinib for second-line treatment in Patients With advanced or metastatic biliary tract carcinoma.

NCT ID: NCT06463522 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma

Start date: July 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1, open label clinical trial of tumor-infiltrating lymphocytes for the treatment of patients with hepatocellular carcinoma. The purpose of this study is to assess the safety of tumor-infiltrating lymphocytes therapy in patients with hepatocellular carcinoma.

NCT ID: NCT06463444 Recruiting - HCC Clinical Trials

Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models

Start date: June 1, 2024
Phase: Phase 1
Study type: Interventional

Surgery is the main curative treatment for hepatocellular carcinoma(HCC) patients, but 70%-80% of HCC patients are in the middle and advanced stages at the time of diagnosis and cannot be surgically resected. Local and systemic therapy are the main treatments for unresectable HCC. Two recent trials of HAIC combined with PD-1 monoclonal antibody and targeted therapy reported objective response rates (ORR) as high as 43.3% to 77.1%.

NCT ID: NCT06463392 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Deep Learning-based sbORN Diagnostic Model

Start date: June 20, 2024
Phase:
Study type: Observational

Skull-base osteonecrosis (sbORN) is a severe long-term complication of nasopharyngeal carcinoma (NPC) post radiotherapy, which significantly diminish the quality of life, increase the risk of internal carotid artery rupture, and is frequently misdiagnosed as NPC recurrence. Novel diagnostic tools are therefore clinically significant. In this study, the investigators seek to ask if a deep-learning-based model shows a significantly higher sensitivity than radiologists. With a cross-sectional design, the investigators aim to recruit 312 participants in Sun Yat-sen Memorial Hospital, Guangzhou, China that meet the eligibility criteria.

NCT ID: NCT06463366 Recruiting - Liver Stiffness Clinical Trials

Multifrequency MRE for Assessing Chronic Hepatic Disease

Start date: July 1, 2024
Phase:
Study type: Observational

To construct a novel, non-invasive, accurate, and convenient method to achieve the degree of liver damage is an important general problem in the management of patients with chronic liver disease. The investigators would like to develop non invasive advanced Magnetic Resonance Imaging (MRI) techniques (MR elastography, MRI-PDFF) to assess the degree of liver damage in patients with chronic liver disease. These techniques could reach high diagnostic performance for detection of liver fibrosis, inflammation and liver fat content; and could decrease the number of liver biopsies, which have risks and sample only a small portion of the liver.

NCT ID: NCT06463236 Recruiting - Clinical trials for Anemia of Chronic Kidney Disease

Clinical Validation of the Management Process for Renal Anemia in Maintenance Hemodialysis Patients

Start date: June 14, 2024
Phase: N/A
Study type: Interventional

This test aims to verify that the management process of renal anemia in maintenance hemodialysis patients can improve the hemoglobin compliance rate better than that of anemia management by primary doctors, and promote the system at the grassroots level to guide primary doctors in anemia management and improve the management standard of renal anemia in maintenance hemodialysis patients through prospective randomized controlled trials. To improve the anemia compliance rate of maintenance hemodialysis patients, and to improve the basic doctors' grasp of the anemia management guidelines, consensus and standard operating procedures.